HKSE:06990 (China)
Â
Class H Shares
HK$
523
-15 (-2.79%)
Aug 24
Business Description
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
NAICS : 541714
SIC : 8731
ISIN : CNE1000062J1
Share Class Description:
HKSE:06990: Class H SharesTotal Employee Number:
2,045Compare
Compare
Traded in other countries / regions
06990.Hong Kong Index Membership
Hong Kong Stock Connect IPO Date
2023-07-11Description
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a biopharmaceutical company committed to the R&D, manufacturing, and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population. Currently, the company has two ADC drugs as Core Products, namely, sac-TMT and trastuzumab botidotin.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 58.73 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | 1.01 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 62.16 | |||||
Beneish M-Score | -2.22 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 33.3 | |||||
3-Year EBITDA Growth Rate | 13.1 | |||||
3-Year EPS without NRI Growth Rate | 15.7 | |||||
3-Year FCF Growth Rate | 2.9 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 51.39 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 63.05 | |||||
9-Day RSI | 61.03 | |||||
14-Day RSI | 59.51 | |||||
3-1 Month Momentum % | 12.76 | |||||
6-1 Month Momentum % | 22.78 | |||||
12-1 Month Momentum % | 12.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.34 | |||||
Quick Ratio | 6.03 | |||||
Cash Ratio | 5.49 | |||||
Days Inventory | 162.71 | |||||
Days Sales Outstanding | 33.07 | |||||
Days Payable | 271.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.6 | |||||
Shareholder Yield % | 0.03 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 74.6 | |||||
Operating Margin % | -37.53 | |||||
Net Margin % | 7.95 | |||||
EBITDA Margin % | 3.97 | |||||
FCF Margin % | 20.4 | |||||
OCF Margin % | 25.69 | |||||
ROE % | 3.3 | |||||
ROA % | 2.75 | |||||
ROIC % | -63.69 | |||||
3-Year ROIIC % | 2.18 | |||||
ROC (Joel Greenblatt) % | 11.4 | |||||
ROCE % | 1.61 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 655.39 | |||||
Forward PE Ratio | 7805.95 | |||||
PE Ratio without NRI | 690.89 | |||||
PS Ratio | 51.79 | |||||
PB Ratio | 19.76 | |||||
Price-to-Tangible-Book | 19.76 | |||||
Price-to-Free-Cash-Flow | 253.75 | |||||
Price-to-Operating-Cash-Flow | 201.52 | |||||
EV-to-EBIT | 1277.36 | |||||
EV-to-Forward-EBIT | -779.52 | |||||
EV-to-EBITDA | 1277.36 | |||||
EV-to-Revenue | 50.76 | |||||
EV-to-Forward-Revenue | 45.7 | |||||
EV-to-FCF | 248.83 | |||||
Price-to-GF-Value | 2.05 | |||||
Price-to-Graham-Number | 24.63 | |||||
| Price-to-Net-Current-Asset-Value | 23.29 | |||||
| Price-to-Net-Cash | 27.8 | |||||
Earnings Yield (Greenblatt) % | 0.08 | |||||
FCF Yield % | 0.38 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 2,355.12 | ||
| EPS (TTM) (HK$) | 0.798 | ||
| Beta | 1.0458 | ||
| 3-Year Sharpe Ratio | 1.38 | ||
| 3-Year Sortino Ratio | 3.63 | ||
| Volatility % | 35.65 | ||
| 14-Day RSI | 59.51 | ||
| 14-Day ATR (HK$) | 28.227394 | ||
| 20-Day SMA (HK$) | 513.665 | ||
| 12-1 Month Momentum % | 12.71 | ||
| 52-Week Range (HK$) | 339.6 - 581 | ||
| Shares Outstanding (Mil) | 239.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Frequently Asked Questions
What is Sichuan Kelun-Biotech Biopharmaceutical Co Ltd(HKSE:06990)'s stock price today?
The current price of HKSE:06990 is HK$523.00. The 52 week high of HKSE:06990 is HK$581.00 and 52 week low is HK$339.60.
When is next earnings date of Sichuan Kelun-Biotech Biopharmaceutical Co Ltd(HKSE:06990)?
The next earnings date of Sichuan Kelun-Biotech Biopharmaceutical Co Ltd(HKSE:06990) is .
Does Sichuan Kelun-Biotech Biopharmaceutical Co Ltd(HKSE:06990) pay dividends? If so, how much?
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd(HKSE:06990) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers